Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

HOTH

Hoth Therapeutics Inc

Dec 10 • 04:00PM ET

0.8550

Dollar change -0.0040
Percentage change -0.47	%

Healthcare • Biotechnology • USA • NASD

Peers: TGTX IMUX GNPX OCGN LXRX PSTV AYTU

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.40	Insider Own	0.93%	Shs Outstand	6.90M	Perf Week	-1.00%
Market Cap	5.90M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	63.77%	Shs Float	6.84M	Perf Month	-6.86%
Income	-7.51M	PEG	-	EPS next Q	-0.30	Inst Own	5.31%	Short Float	6.70%	Perf Quarter	-28.15%
Sales	0.00M	P/S	-	EPS this Y	44.78%	Inst Trans	5.08%	Short Ratio	0.39	Perf Half Y	-13.46%
Book/sh	1.09	P/B	0.79	EPS next Y	50.39%	ROA	-73.63%	Short Interest	0.46M	Perf Year	-32.68%
Cash/sh	1.16	P/C	0.74	EPS next 5Y	-	ROE	-83.41%	52W Range	0.58 - 1.73	Perf YTD	-40.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.18%	ROI	-100.14%	52W High	-50.58%	Beta	0.74
Dividend TTM	-	Quick Ratio	10.16	Sales past 5Y	-	Gross Margin	-	52W Low	47.41%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	10.16	EPS Y/Y TTM	86.68%	Oper. Margin	-	RSI (14)	51.33	Volatility	4.68% 7.53%
Employees	6	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	48.45%	Payout	-	Rel Volume	0.08	Prev Close	0.86
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	1.17M	Price	0.86
SMA20	2.12%	SMA50	0.54%	SMA200	-14.28%	Trades		Volume	102,103	Change	-0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-19	Initiated	The Benchmark Company	Speculative Buy	$10

Nov-22-24 12:25PM	MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 (Barrons.com)
Nov-20-24 07:38AM	Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset (PR Newswire)
Oct-29-24 12:43PM	Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study (PR Newswire) +10.84%
Oct-15-24 06:38AM	Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway (PR Newswire) +8.11%
Sep-17-24 07:57AM	Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ (PR Newswire) +5.94%
10:32AM	Loading…
Sep-05-24 10:32AM	Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial (PR Newswire) +77.49%
08:03AM	Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 (PR Newswire)
Aug-16-24 06:33AM	Hoth and Aronnax partner for HT-KIT cancer therapy development (Pharmaceutical Technology) +14.10%
Aug-15-24 08:04AM	Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic (PR Newswire)
Jul-24-24 06:30AM	Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment (PR Newswire) +10.09%
Jul-16-24 08:31AM	Hoth Therapeutics Expands Clinical Trial for Cancer Patients (PR Newswire) +5.68%
Jun-27-24 06:52AM	HOTH Stock Earnings: Hoth Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Jun-11-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-10-24 08:11AM	Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery (PR Newswire) -8.26%
May-15-24 09:54AM	HOTH Stock Earnings: Hoth Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Loading…
May-01-24 08:00AM	Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 (PR Newswire)
Mar-27-24 02:00PM	Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds (PR Newswire) -7.38%
08:27AM	Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment (PR Newswire)
Mar-20-24 05:38AM	Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data (Zacks) +8.15%
Mar-19-24 08:21AM	Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ (PR Newswire) +17.39%
Feb-29-24 08:38AM	Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio (PR Newswire) -5.38%
Feb-26-24 08:11AM	Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic (PR Newswire)
Feb-13-24 11:45AM	Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 (PR Newswire)
Jan-18-24 08:20AM	Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients (PR Newswire) +6.20%
Dec-27-23 08:21AM	Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami (PR Newswire) +19.26%
Dec-05-23 08:33AM	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies (PR Newswire)
Nov-14-23 08:37AM	Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT (PR Newswire)
Nov-10-23 08:00AM	Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023 (PR Newswire)
Oct-05-23 10:03AM	Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery (PR Newswire)
Oct-02-23 08:33AM	FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients (PR Newswire)
02:38PM	Loading…
Sep-15-23 02:38PM	Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire)
Sep-13-23 01:43PM	Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire) -28.36%
08:16AM	Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia (PR Newswire)
Sep-11-23 10:04AM	Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients (PR Newswire) +10.16%
Sep-06-23 08:12AM	Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa (PR Newswire) +5.53%
Aug-09-23 08:13AM	Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease (PR Newswire) +11.11%
Jul-25-23 08:12AM	Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial (PR Newswire)
Jul-19-23 08:02AM	Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic (PR Newswire)
Jun-14-23 08:12AM	Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site (PR Newswire) +7.69%
Jun-06-23 03:01PM	Hoth Therapeutics Stock Almost Doubles in Tuesday's Trading Session, Here's Why (Benzinga) +78.19%
08:02AM	Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease (PR Newswire)
May-12-23 08:38AM	Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge (PR Newswire)
Apr-26-23 04:21PM	From Alzheimer's to PAH: Hoth Therapeutics and Algorithm Sciences Combine to Pursue High Blood Pressure Solutions (Benzinga) -8.42% -5.75%
08:18AM	Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge (PR Newswire)
Mar-08-23 09:09AM	Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
Feb-16-23 08:35AM	Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity (PR Newswire) +21.15%
Feb-08-23 10:42AM	Why Are Hoth Therapeutics Shares Moving Today? (Benzinga) -19.07%
08:43AM	Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ (PR Newswire)
Jan-25-23 08:27AM	Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
Jan-03-23 04:38PM	Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) -15.90%
Dec-29-22 08:00PM	Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) +143.64% -27.24%
09:08AM	FDA Signs Off Hoth Therapeutics' Trial Application For HT-001 For Skin Cancers (Benzinga)
08:45AM	Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
Dec-01-22 10:45AM	Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001 (PR Newswire)
Nov-09-22 12:38PM	Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire) -6.71%
Oct-31-22 11:39AM	Hoth Therapeutics' Atopic Dermatitis Candidate Shows Improvement In Severity, Shares Jump (Benzinga)
09:57AM	HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS (PR Newswire)
Oct-24-22 04:15PM	Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 (PR Newswire) -26.37%
Sep-20-22 09:05AM	Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke (PR Newswire)
Sep-06-22 08:21AM	Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders (PR Newswire)
Aug-16-22 03:00PM	Sidoti's August Micro-Cap Virtual Conference (ACCESSWIRE)
Aug-12-22 01:48PM	Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference (PR Newswire)
Jul-12-22 02:24PM	Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program (Benzinga)
10:26AM	Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model (PR Newswire)
Jun-29-22 01:25PM	Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (PR Newswire)
Jun-21-22 12:30PM	Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis (PR Newswire)
Jun-15-22 12:30PM	Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022 (PR Newswire)
Jun-09-22 08:18AM	Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ (PR Newswire)
May-06-22 09:02AM	10 Biotech Penny Stocks Redditors Love (Insider Monkey)
May-03-22 08:09AM	Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort (PR Newswire)
Apr-19-22 03:29PM	Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury (Benzinga)
10:29AM	Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury (PR Newswire)
Apr-14-22 01:02PM	Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market (PR Newswire) +6.15%
Apr-12-22 08:17AM	Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference (PR Newswire) -31.43%
Apr-11-22 11:31PM	Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market (PR Newswire) +70.48%
04:21PM	Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
03:49PM	Pair of Drugmakers Soar in Meme-Like Session on Study Results (Bloomberg)
10:17AM	Hoth Therapeutics' Novel Cancer Drug Prevented Cell Growth, Induced Cell Death Over 72 hours (Benzinga)
09:47AM	BioMed Leaders: Hoth Therapeutics, Nova Mentis Life Sciences, Tonix Pharmaceuticals, and MedAvail; Visionary CEOs Report Latest Advances in Novel Therapeutics for Autism, Cancer, and Fibromyalgia, and Drug Affordability. (GlobeNewswire)
08:05AM	Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells (PR Newswire)
07:57AM	Midday Stock Movers: Hoth Therapeutics and Veru Soar (Investing.com)
06:21AM	Hoth Therapeutics Doubles After Tests Show Cancer Trial Drug Is Effective (Investing.com)
Apr-01-22 08:02AM	Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention (PR Newswire)
Mar-22-22 09:48AM	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance (PR Newswire) +5.69%
Mar-11-22 08:00AM	Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat Mastocytosis (PR Newswire) -23.43%
Feb-09-22 10:10AM	Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients (PR Newswire)
Feb-07-22 08:02AM	Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference (PR Newswire) -6.21%
Jan-31-22 08:17AM	Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board (PR Newswire) +7.78%
Jan-05-22 05:18AM	Will Hoth Therapeutics (NASDAQ:HOTH) Spend Its Cash Wisely? (Simply Wall St.) -10.77%
Jan-04-22 02:13PM	HOTH Stock Alert: Why Is Hoth Therapeutics Skyrocketing Today? (InvestorPlace) +84.50%
08:01AM	Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid in Alzheimer's Disease (PR Newswire)
Dec-21-21 07:59AM	Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis (PR Newswire)
Dec-08-21 08:00AM	Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics (PR Newswire)
Nov-30-21 08:00AM	Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way (PR Newswire)
Nov-16-21 08:30AM	Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT (PR Newswire)
Nov-08-21 08:38AM	Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic (PR Newswire)
Oct-19-21 12:47PM	Hoth Therapeutics Extends Partnership Agreement with REPROCELL (PR Newswire)
Oct-12-21 10:04AM	Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans (Benzinga)
10:00AM	Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients (PR Newswire)
Sep-22-21 07:00AM	Hoth Therapeutics, Inc.: Invitation to the Benzinga Healthcare Small Cap Conference (Newsfile)

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Knie Robb	CEO and President	Aug 16 '24	Buy	0.67	25,000	16,750	58,131	Aug 19 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HOTH

Hoth Therapeutics Inc

Upgrade your FINVIZ experience